Skip to content
BY-NC-ND 3.0 license Open Access Published by De Gruyter Open Access September 26, 2006

Biomarkers in breast cancer

Graciela Laguens, Silvia Coronato and Wanda Girolamo
From the journal Open Medicine

Abstract

Breast cancer is one of the most frequently diagnosed cancers among women in the western world. Due to the aggressive behaviour of some specific types and the possibility of an early diagnosis, breast cancer has been constantly studied. Tumour size, histological type, cellular and nuclear characteristics, mitotic index, vascular invasion, hormonal receptors and axillary lymph node status are biomarkers routinely used. However, these parameters are not enough to predict the course of this disease. Molecular biology advances have made it possible to find new markers, which have already been incorporated to the clinical practice. Their ultimate goal is to reduce mortality by identifying women at risk for the development of this disease, help diagnosis, determine prognosis, detect recurrences, monitor and guide treatment, and in particular cancers they are suited for general screening. Tumour markers in breast cancer were ranked in categories reflecting their clinical utility, according to the American College of Pathologists.

This article focuses on traditional and new molecular markers stratifying them into categories and emphasizing their relevance in the routine evaluation of patients with breast cancer.

[1] K. Dhingra and G.N. Hortobagyi: “Critical evaluation of prognostic factors”, Sem. Oncol., Vol. 23, (1996), pp. 436–445. Search in Google Scholar

[2] J. Sjostrom, C. Blomqvist, P. Heikkila, K.V. Bogulawski, A. Raiseanen-Sokolowski, N.O. Bengtsson, I. Mjaaland, P. Malmstron, B. Ostenstadt, J. Berg, E. Wist, V. Valvere and E. Saksela: “Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer”, Clin. Cancer Res., Vol. 6(8), (2000), pp. 3103–3110. Search in Google Scholar

[3] K.L. Cheung, C.R. Graves and J.F. Robertson: “Tumour marker measurements in the diagnosis and monitoring of breast cancer”, Cancer Treat. Res., Vol. 26, (2000), pp. 91–102. http://dx.doi.org/10.1053/ctrv.1999.015110.1053/ctrv.1999.0151Search in Google Scholar

[4] V. Stearns, H. Yamauchi and D.F. Hayes: “Circulating tumour markers in breast cancer: accepted utilities a novel prospect”, Breast Cancer Res. Treat., Vol. 52, (1998), pp. 239–259. http://dx.doi.org/10.1023/A:100613761915310.1023/A:1006137619153Search in Google Scholar

[5] J. Martinez-Trufero, A.R. de Lobera, J. Lao, T. Puertolas, A. Artal-Cortes, M. Zorrilla, V. Alonso, R. Pazo, M.I. Valero, M.J. Rios-Mitchell, V. Calderero, A. Herrero and A. Anton: “Serum markers and prognosis in locally advanced breast cancer”, Tumori, Vol. 91, (2005), pp. 522–530. Search in Google Scholar

[6] D. Haidopoulos, M.M. Konstadoulakis, P.T. Antonakis, D.G. Alexiou, A.M. Manouras, S.M. Katsaragakis and G.F. Androulakis: “Circulating anti-CEA antibodies in the sera of patients with breast cancer”, Eur. J. Surg. Oncol., Vol. 26, (2000), pp. 742–746. http://dx.doi.org/10.1053/ejso.2000.099610.1053/ejso.2000.0996Search in Google Scholar

[7] D. Allred, J. Harvey, M. Berardo and G. Clark: “Prognostic and predictive factors in breast cancer by immunohistochemical analysis”, Mod. Pathol., Vol. 11, (1998), pp. 155–168. Search in Google Scholar

[8] P.L. Fitzgibbons, D.L. Page, D. Weaver, A.D. Thor, D.C. Allred, G.M. Clark, S.G. Ruby, F. O’Malley, J.F. Simpson, J.L. Conolly, D.F. Hayes, S.B. Edge, A. Lichter and S.J. Schnitt: “Prognostic factors in breast cancer”, Arch. Pathol. Lab. Med., Vol. 124, (2000), pp. 966–978. Search in Google Scholar

[9] R. Heimann and S. Hellman: “Individual characterisation of the metastatic capacity of human breast carcinoma”, Eur. J. Cancer, Vol. 36, (2000), pp. 1631–1639. http://dx.doi.org/10.1016/S0959-8049(00)00151-910.1016/S0959-8049(00)00151-9Search in Google Scholar

[10] E.L. Dupont, M.A. Kuhn, C. McCann, C. Salud, J.L. Spanton and C.E. Cox: “The role of sentinel lymph node biopsy in women undergoing prophylactic mastectomy”, Am. J. Surg., Vol. 180, (2000), pp. 274–277. http://dx.doi.org/10.1016/S0002-9610(00)00458-X10.1016/S0002-9610(00)00458-XSearch in Google Scholar

[11] P.J. Borgstein, S. Meijer, R.J. Pijpers and P.J. van Diest: “Functional lymphatic anatomy for sentinel node biopsy in breast cancer: echoes from the past and the periareolar blue method”, Ann. Surg., Vol. 232, (2000), pp. 81–89. http://dx.doi.org/10.1097/00000658-200007000-0001210.1097/00000658-200007000-00012Search in Google Scholar PubMed PubMed Central

[12] H.J.G. Bloom and W.W. Richardson: “Histological grading and prognosis in breast cancer: A study of 1709 cases of which 359 have been followed for 15 years”, Br. J. Cancer, Vol. 2, (1957), pp. 353–377. Search in Google Scholar

[13] B. Helpap: “Nucleolar grading of breast cancer”, Virchows Archiv. A Pathol. Anat. Vol. 415 (1989), pp. 501–508. http://dx.doi.org/10.1007/BF0071864310.1007/BF00718643Search in Google Scholar PubMed

[14] I.O. Elis, C.W. Elston and R.W. Blamey: “The Nottingham prognosis index (NPI) a combination of multiple prognostic factors derived from the Nottingham Tenovus primary cancer study”, Mod. Pathol., Vol. 4, (1991), p. 11. Search in Google Scholar

[15] E.R. Fisher and B. Fisher: “Lobular carcinoma of the breast: an overview”, Ann. Surg., Vol. 185, (1977), pp. 377–385. http://dx.doi.org/10.1097/00000658-197704000-0000110.1097/00000658-197704000-00001Search in Google Scholar PubMed PubMed Central

[16] X. Cui, R. Schiff, G. Arpino, C.K. Osborne and A.V. Lee: “Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy”, J. Clin. Oncol., Vol. 23, (2005), pp. 7721–7735. http://dx.doi.org/10.1200/JCO.2005.09.00410.1200/JCO.2005.09.004Search in Google Scholar PubMed

[17] B. Jasani, A Douglas-Jones, A. Rhodes, S. Wozniak, P.J. Barrett-Lee, J. Gee and R. Nicholson: “Measurement of estrogen receptor status by immunocytochemistry in paraffin wax sections”, Methods Mol. Med., Vol. 120, (2006), pp. 127–146. Search in Google Scholar

[18] J.D. Yager and N.E. Davidson: “Estrogen carcinogenesis in breast cancer”, N. Engl. J. Med., Vol. 354, (2006), pp. 270–282. http://dx.doi.org/10.1056/NEJMra05077610.1056/NEJMra050776Search in Google Scholar PubMed

[19] X. Chen, C. Danes, M. Lowe, T.W. Herliczek and K. Keyomarsi: “Activation of the Estrogen-Signaling Pathway by p21 (WAF1/CIP1) in Estrogen Receptor-negative breast cancer cells”, J. Natl. Cancer Inst., Vol. 92, (2000), pp. 1403–1413. http://dx.doi.org/10.1093/jnci/92.17.140310.1093/jnci/92.17.1403Search in Google Scholar

[20] R. Schiff, S.A. Massarweh, J. Shou, L. Bharwani, G. Arpino, M. Rimawi and C.K. Osborne: “Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators”, Cancer Chemother. Pharmacol., Vol. 56, (2005), pp. 10–20. http://dx.doi.org/10.1007/s00280-005-0108-210.1007/s00280-005-0108-2Search in Google Scholar

[21] N. Normanno, M. Di Maio, E. Di Maio, A. De Luca, A. de Matteis, A. Giordano and F. Perrone: “Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer”, Endocr. Relat. Cancer, Vol. 12, (2005), pp. 721–747. http://dx.doi.org/10.1677/erc.1.0085710.1677/erc.1.00857Search in Google Scholar

[22] A. Starr, K. Bloom, D. Oleske and M. Cobleigh: “Comparison of fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) in determining HER-2/neu status in breast cancer patients”, Proc. Am. Soc. Clin. Oncol., 2000 ASCO Annual Meeting, abstract No. 2610. Search in Google Scholar

[23] A.A. Sahin: “Biologic and clinical significance of HER-2/neu (c-erbB-2) in breast cancer”, Adv. Anat. Pathol., Vol. 7, (2000), pp. 158–166. http://dx.doi.org/10.1097/00125480-200007030-0000510.1097/00125480-200007030-00005Search in Google Scholar

[24] F.J. Esteva, C.D. Cheli, H. Fritsche, M.D. Slamon, R.P. Thiel, D. Luftner and G. Farooq: “Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies”, Breast Cancer Res., Vol. 7, (2005), pp. 436–443. http://dx.doi.org/10.1186/bcr102010.1186/bcr1020Search in Google Scholar

[25] L.D. Miller, J. Smeds, J. George, V.B. Vega, L. Vergara, A. Ploner, Y. Pawitan, P. Hall, S. Klaar, E.T. Liu and J. Bergh: “An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival”, Proc. Natl. Acad. Sci. USA., Vol. 102, (2005), pp. 13550–13555. http://dx.doi.org/10.1073/pnas.050623010210.1073/pnas.0506230102Search in Google Scholar

[26] S.J. Schnitt: “Traditional and Newer Pathologic Factors”, J. Nat. Cancer Ins. Mon., Vol. 30, (2001), pp. 22–26. Search in Google Scholar

[27] H. Takei, Y. Iino, J. Horiguchi, M. Maemura, H. Nagaoka, Y. Koibuchi, T. Yokoe, T. Oyama and Y. Moreshita: “Highest microvessel count as a long-term prognostic factor in Japanase breast cancer patients”, Cancer Lett., Vol. 156, (2000), pp. 109–116. http://dx.doi.org/10.1016/S0304-3835(00)00449-310.1016/S0304-3835(00)00449-3Search in Google Scholar

[28] G. Gasparini: “Clinical significance of determination of surrogate markers of angiogenesis in breast cancer”, Crit. Rev.Oncol. Hematol., Vol. 37, (2001), pp. 97–114 Search in Google Scholar

[29] J. Boyle: “Histological measurement of tumour angiogenesis”, Eur. J. Cancer, Vol. 39, (2003), pp. 859–860. http://dx.doi.org/10.1016/S0959-8049(03)00121-710.1016/S0959-8049(03)00121-7Search in Google Scholar

[30] D. Cruz, C. Valenti, A. Dias, M. Seixas and F. Schmitt: “Microvessel density counting in breast cancer. Slides vs. digital images”, Anal. Quant. Cytol. Histo., Vol. 23, (2001), pp. 15–20. Search in Google Scholar

[31] G. Gasparini: “Prognostic value of vascular endothelial growth factor in breast cancer”, Oncologist, Vol. 5, (2000), pp. 37–44. http://dx.doi.org/10.1634/theoncologist.5-suppl_1-3710.1634/theoncologist.5-suppl_1-37Search in Google Scholar PubMed

[32] G. Callagy, E. Dimitriadis, J. Harmey, D. Bouchier-Hayes, M. Leader and E. Kay: “Immunohistochemical measurement of tumor vascular endothelial growth factor in breast cancer. A more reliable predictor of tumor stage than microvessel density or serum vascular endothelial growth factor”. Appl. Immunohistochem. Molecul. Morphol., Vol. 8, (2000), pp. 104–109. http://dx.doi.org/10.1097/00022744-200006000-0000410.1097/00022744-200006000-00004Search in Google Scholar

[33] N. Boudreau and C. Myers: “Breast cancer-induced angiogenesis: multiple mechanisms and the role of the microenvironment”, Breast Cancer Res., Vol. 5, (2003), pp. 140–146. http://dx.doi.org/10.1186/bcr58910.1186/bcr589Search in Google Scholar

[34] P.H. Tan, B.H. Bay, G. Yip, S. Selvarrajan, P. Tan, J. Wu, C.H. Lee and K. B. Lee: “Immunohistochemical detection of Ki 67 in breast cancer correlates with transcriptional regulation of genes related to apoptosis and cell death”, Mod. Pathol., Vol. 18, (2005), pp. 374–381. http://dx.doi.org/10.1038/modpathol.380025410.1038/modpathol.3800254Search in Google Scholar

[35] S.A. Aziz, S. Pervez, S.M. Khan, N. Kayani and M. I. Nasir: “Prognostic value of proliferating cell nuclear antigen (PCNA) in infiltrating ductal carcinoma breast”, J. Coll. Physicians Surg. Pak., Vol. 15, (2005), pp. 225–229. Search in Google Scholar

[36] A. Sidoni, G.A. Cavalieri, G. D’Amico, G. Brachelente and E. Bucchiarelli: “Biopathological significance of single cell DNA aneuploidy measured by static cytometry in breast cancer”, The Breast, Vol. 10, (2001), pp. 325–329. http://dx.doi.org/10.1054/brst.2000.024910.1054/brst.2000.0249Search in Google Scholar

[37] J. Adams, P.J. Carder, S. Downey, M.A. Forbes, K. MacLennan, V. Allgar, S. Kaufman, S. Hallam, R. Bicknell, J.J. Walker, F. Cairnduff, P.J. Selby, T.J. Perren, M. Lansdown and R.E. Banks: “Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum and tissue VEGF and microvessel density and effects of tamoxifen”, Cancer Res., Vol. 60, (2000), pp. 2898–2905. Search in Google Scholar

[38] R.S. Rampaul, S.E. Pinder, R.I. Nicholson, W.J. Gullick, J.F. Robertson and I.O. Ellis: “Clinical value of epidermal growth factor receptor expression in primary breast cancer”, Adv. Anat. Pathol., Vol. 12, (2005), pp. 271–273. http://dx.doi.org/10.1097/01.pap.0000184178.43048.8010.1097/01.pap.0000184178.43048.80Search in Google Scholar

[39] H.W. Lo, S.C. Hsu and M.C. Hung: “EGFR signaling pathway in breast cancers: from tradicional signal transduction to direct nuclear translocalization”, Breast Cancer Res. Treat., Vol. 28 (2005), pp. 1–8. Search in Google Scholar

[40] H. Rochefort, M. Garcia, M. Glondu, V. Laurent, E. Liaudet, J. Rey and P. Roger: “Cathepsin D in breast cancer: mechanisms and clinical applications, a 1999 overview”, Clin. Chim. Acta, Vol. 291, (2000), pp. 157–170. http://dx.doi.org/10.1016/S0009-8981(99)00226-010.1016/S0009-8981(99)00226-0Search in Google Scholar

[41] A.M. Billgren, L.E. Rutqvist, H. Johansson, T. Hagerstrom and L. Skoog: “The role of cathepsin D and PAI-1 in primary invasive breast cancer as prognosticators and predictors of treatment benefit with adjuvant tamoxifen”, Eur. J. Cancer, Vol. 36, (2000), pp. 1374–1380. http://dx.doi.org/10.1016/S0959-8049(00)00114-310.1016/S0959-8049(00)00114-3Search in Google Scholar

[42] R. González Cámpora, M. Galera Ruiz, F. Vázquez Ramírez, J.J. Rios Martín, J.M. Fernández Santos, M.M. Martos and A. Gómez Pascual: “Apoptosis in breast carcinoma”, Pathol. Res. Pract., Vol. 196, (2000), pp. 167–174. Search in Google Scholar

[43] B. Agrawal, M. Krantz, M. Reddish and B. Longenecker: “Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2”. Nat. Med., Vol. 4, (1998), pp. 43–49. http://dx.doi.org/10.1038/nm0198-04310.1038/nm0198-043Search in Google Scholar

[44] E.A. Rakha, R.W. Boyce, D. Abd El-Rehim, T. Kurien, A.R. Green, E.C. Paish, J.F. Robertson and I.O. Ellis: “Expression of mucins (MUC1, MUC5AC and MUC6) and their prognostic significance in human breast cancer”, Mod. Pathol., Vol. 8, (2005), pp. 1295–1304. http://dx.doi.org/10.1038/modpathol.380044510.1038/modpathol.3800445Search in Google Scholar

[45] N. Berois N, M. Varangot and C. Sonora: “Detection of bone marrow-disseminated breast cancer cells using an RT-PCR assay of MUC5b mRNA”, Int. J.Cancer, Vol. 103, (2003), pp. 550–555. http://dx.doi.org/10.1002/ijc.1085310.1002/ijc.10853Search in Google Scholar

[46] K. Yoshikawa, T. Ogawa, R. Baer, H. Hemmi, K. Honda, A. Yamauchi, T. Inamoto, K. Ko, S. Yazumi, H. Motoda, H. Kodama, S. Noguchi, A.F. Gazdar, Y. Yamaoka and R. Takahashi: “Abnormal expression of BCRA1 and BCRA2-interactive DNArepair proteins in breast carcinomas”, Int. J. Cancer, Vol. 88, (2000), pp. 28–36. http://dx.doi.org/10.1002/1097-0215(20001001)88:1<28::AID-IJC5>3.0.CO;2-410.1002/1097-0215(20001001)88:1<28::AID-IJC5>3.0.CO;2-4Search in Google Scholar

[47] J. Rogozinska-Szczepka, B. Utracka-Hutka, E. Grzybowska, B. Maka, E. Nowicka, A. Smok-Ragankiewicz, H. Zientek, J. Steffen and A. Wojciechowska-Lacka: “BRCA1 and BRCA2 mutations as prognostic factors in bilateral breast cancer patients”, Ann. Oncol., Vol. 15, (2004), pp. 1373–1376. http://dx.doi.org/10.1093/annonc/mdh35210.1093/annonc/mdh352Search in Google Scholar

[48] P.K. Auvinen, P.K. Lipponen, V.V. Kataja, R.T Johansson and K. J. Syrjanen: “Prognostic significance of TGFa expression in breast cancer”, Acta Oncologica, Vol. 35, (1996), pp. 995–998. Search in Google Scholar

[49] M.J. Duffy: “Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies”, Clin. Chem., Vol. 48, (2002), pp. 1194–1197. Search in Google Scholar

[50] P. Chrzan, J. Skolowski, A. Karmolinski and T. Pawelczyk: “Amplification of cmyc gene and overexpression of c-Myc protein in breast cancer and adjacent nonneoplastic tissue”, Clin. Biochem., Vol. 34, (2001), pp. 557–562. http://dx.doi.org/10.1016/S0009-9120(01)00260-010.1016/S0009-9120(01)00260-0Search in Google Scholar

[51] V. Masciullo, K. Khalili and A. Giordano: “The Rb family of cell cycle regulatory factors: clinical implications” (Review), Int. J. Oncol., Vol. 17, (2000), pp. 897–902. Search in Google Scholar

[52] S. Zhang, S.C. Liu, L.F. Al-Saleem, D. Holloran, J. Babb, X. Guo and A.J. Klein-Szanto: “E2F-1: a proliferative marker of breast neoplasia”, Cancer Epidemiol. Biomarkers Prev., Vol. 9, (2000), pp. 395–401. Search in Google Scholar

[53] S. Coronato, V. Di Girolamo, M. Salas, O. Spinelli and G. Laguens: “Biología de las proteínas del shock térmico”, Medicina, Buenos Aires, Vol 59, (1999), pp. 477–486. Search in Google Scholar

[54] D.R. Ciocca and S.K. Calderwood: “Heat shock proteins in cancer: diagnostic, prognostic, predictive and treatment implications”, Cell Stress Chaperons, Vol. 10, (2005), pp. 86–103. http://dx.doi.org/10.1379/CSC-99r.110.1379/CSC-99r.1Search in Google Scholar PubMed PubMed Central

[55] S.K. Calderwood, M.A. Khaleque, D.B. Sawyer and D.R. Ciocca: “Heat shock proteins in cancer: chaperones of tumorigenesis”, Trends Biochem. Sci., Vol. 31, (2006), pp. 164–172. http://dx.doi.org/10.1016/j.tibs.2006.01.00610.1016/j.tibs.2006.01.006Search in Google Scholar PubMed

[56] G.E. Laguens, S. Coronato, O. Spinelli, R.P. Laguens and V. Di Girolamo: “Can breast cancer Hsp27 (Heat Shock Protein 27000) expression influence axillary lymph node status?”, The Breast, Vol. 10, (2001), pp. 179–181. http://dx.doi.org/10.1054/brst.2000.022110.1054/brst.2000.0221Search in Google Scholar PubMed

[57] A. Stathopoulou, I. Vlachonikolis, D. Mavroudis, M. Perraki, Ch. Kouroussis, S. Apostolaki, N. Malamos, S. Kakolyris, A. Kotsakis, N. Xenidis, D. Reppa and V. Georgoulias: “Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance”, J. Clin. Oncol., Vol. 20, (2002), pp. 3404–3412. http://dx.doi.org/10.1200/JCO.2002.08.13510.1200/JCO.2002.08.135Search in Google Scholar PubMed

[58] N. Xenidis, I. Vlachonikolis, D. Mavroudis, M. Perraki, A. Stathopoulou, N. Malamos, Ch. Kouroussis, S. Kakolyris, S. Apostolaki, N. Vardakis, E. Lianidou and V. Georgoulias: “Peripheral blood circulating cytokeratin-19 mRNA-positive cells after the completion of adjuvant chemotherapy in patients with operable breast cancer”, Ann. Oncol., Vol. 14, (2003), pp. 849–855. http://dx.doi.org/10.1093/annonc/mdg25910.1093/annonc/mdg259Search in Google Scholar PubMed

[59] G. Spizzo, G. Gastl, D. Wolf, E. Gunsilius, M. Steurer, D. Fong, A. Amberger, R. Margreiter and P. Obrist: “Correlation of Cox-2 and Ep-CAM overexpression in human invasive breast cancer and its impact on survival”, Br. J. Cancer, Vol. 88, (2003), pp. 574–578. http://dx.doi.org/10.1038/sj.bjc.660074110.1038/sj.bjc.6600741Search in Google Scholar PubMed PubMed Central

[60] G. Spizzo, P. Obrist, C. Ensinger, I. Theurl, M. Dunser, A. Ramoni, E. Gunsilius, G. Eibl, G. Mikuz and G. Gastl: “Prognostic significance of EP-CAM and Her-2/neu overexpression in invasive breast cancer” Int.J.Cancer, Vol. 98, (2002), pp. 883–888. http://dx.doi.org/10.1002/ijc.1027010.1002/ijc.10270Search in Google Scholar PubMed

[61] J.A. King, S. Ofori-Acquah and T. Stevens: “Activated leukocyte cell adhesion molecule in breast cancer: prognostic indicator”, Breast Cancer Res., Vol. 6, (2004), pp. 478–487. http://dx.doi.org/10.1186/bcr81510.1186/bcr815Search in Google Scholar PubMed PubMed Central

[62] M.J. Duffy: “Predictive markers in breast and other cancers: a review”, Clin. Chem., Vol. 51, (2005), pp. 494–503. http://dx.doi.org/10.1373/clinchem.2004.04622710.1373/clinchem.2004.046227Search in Google Scholar PubMed

[63] I. Benoy, R. Salgado, H. Elst, P. Van Dam, J. Weyler, E. Van Marck, S. Scharpe, P.B. Vermeulen and L.Y. Dirix: “Relative microvessel area of the primary tumour, and not lymph node status, predicts the presence of bone marrow micrometastases in patients with clinically non-metastatic breast cancer”, Breast Cancer Res., Vol. 7, (2005), pp. 210–219. http://dx.doi.org/10.1186/bcr98010.1186/bcr980Search in Google Scholar PubMed PubMed Central

[64] A. Lindblom and A. Liljegren: “Tumour markers in malignancies” B.M.J., Vol. 320, (2000), pp. 424–427. http://dx.doi.org/10.1136/bmj.320.7232.42410.1136/bmj.320.7232.424Search in Google Scholar PubMed PubMed Central

[65] R. Molina, V. Barak, A. van Dalen, M.J. Duffy, R. Einarsson, M. Gion, H. Goike, R. Lamertz, M. Nap, G. Soletormos and P. Stieber: “Tumor markers in breast cancer-European Group on tumor markers recommendations”, Tumour Biol., Vol. 26, (2005), pp. 281–293. http://dx.doi.org/10.1159/00008926010.1159/000089260Search in Google Scholar PubMed

[66] A. Urruticoechea, I.E. Smith and M. Dowsett: “Proliferation marker Ki-67 in early breast cancer”, J. Clin. Oncol., Vol. 23, (2005), pp. 7212–7220. http://dx.doi.org/10.1200/JCO.2005.07.50110.1200/JCO.2005.07.501Search in Google Scholar PubMed

[67] G. Gasparini, R. Longo, M. Toi and N. Ferrara: “Angiogenic inhibitors: a new therapeutic strategy in oncology”, Nat. Clin. Pract. Oncol., Vol. 2, (2005), pp. 562–577. http://dx.doi.org/10.1038/ncponc034210.1038/ncponc0342Search in Google Scholar PubMed

Published Online: 2006-9-26
Published in Print: 2006-12-1

© 2006 Versita Warsaw

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Scroll Up Arrow